CHOICE OF TREATMENT OPTIONS FOR CYSTIC LYMPHSTIC MALFORMATIONS IN THE HEAD AND NECK REGION: TREATMENT EXPERIENCE OF 81 CHILDREN
DOI:
https://doi.org/10.11603/ijmmr.2413-6077.2017.2.8381Keywords:
lymphatic malformations, sclerotherapy, OK-432, children.Abstract
Background. Surgery has previously been the only treatment for lymphatic malformations (LMs), but in the head and neck region is challenging due to the risk of scarring, nerve damage, recurrence. Sclerotherapy may be a perfect alternative.
Objective. The aim of the study is to determine the efficacy and safety of the OK-432 sclerotherapy in the children with craniofacial LMs.
Methods. 81 children with head and neck LM between December 2010 and March 2017were involved into the study. The follow-up period was from 6 to 79 months. According to the size of cysts, LMs were classified into macrocystic, microcystic, and mixed. The result of the treatment of LMs was determined by the percentage of reduction in size as excellent (decrease by more than 90%), good (by 50%-89%), satisfactory (by 20%-49%) and none (by less than 20%).
Results. The macrocystic LMs diagnosed in 41.97% of patients, microcystic - in 12.35%, and mixed – in 45.68% of children. OK-432 sclerotherapy only was performed for 83.9% of patients and in 12.3% in combination with surgery. The range of sclerotherapy sessions was from 1 to 11. An excellent result in 96.97% of cases was evidenced in the patients with macrocystic LM. Poor result was proved in the patients with microcystic LMs; the most of them (55.56%) had satisfactory result. In the patients with mixed LM, an excellent and good result was evidenced in 83.33%. After 198 sessions of OK-432 sclerotherapy, complications associated with the treatment occurred in 5 (2.52%) cases.
Conclusions. OK-432 sclerotherapy is a safe and effective treatment of head and neck LMs in children. Macrocystic LMs proved the best response to OK-432 treatment.
References
Elluru R, Balakrishnan K, Padua H. Lymphatic malformations: Diagnosis and management. Semin Pediatr Surg. 2014;23(4):178–85. doi: 10.1053/j.sempedsurg.2014.07.002.
Mulliken JB, Glowacki J. Hemangiomasand vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69(3):412–22.
Wassef M, Blei F, Adams D, Alomari A, Baselga E, Berenstein A, et al. Vascular Anomalies Classification: Recommendations From the International Society for the Study of Vascular Anomalies. Pediatrics. 2015 Jul;136(1):e203–14. doi: 10.1542/peds.2014-3673.
Perkins J, Manning S, Tempero R, Cunningham M, Edmonds J, Hoffer F, et al. Lymphatic malformations: Current cellular and clinical investigations. Otolaryngol Head Neck Surg. 2010;142(6):789–94. doi: 10.1016/j.otohns.2010.02.025.
Churchill P, Otal D, Pemberton J, Ali A, Flageole H, Walton JM. Sclerotherapy for lymphatic malformations in children: a scoping review. J Pediatr Surg. 2011;46(5):912–22. doi: 10.1016/j.jpedsurg.2011.02.027.
Chen E, Hostikka S, Oliaei S, Duke W, Schwartz S. Perkins J. Similar Histologic Features and Immunohistochemical Staining in Microcystic and Macrocystic Lymphatic Malformations. Lymphat Res Biol. 2009;7(2):75–80. doi: 10.1089/lrb.2009.0003.
Ardici B, Karnak I, Ciftci AO, Tanyel FC, Şenocak ME. Sclerotherapy with bleomycin versus surgical excision for extracervical cystic lymphatic malformations in children. Surg Today. 2016;46(1):97–101. 10.1007/s00595-015-1128-0.
Weitz-Tuoretmaa A, Rautio R, Valkila J, Keski-Säntti H, Keski-Nisula L, Laranne J. Efficacy of OK-432 sclerotherapy in treatment of lymphatic malformations: long-term follow-up results. Eur Arch Otorhinolaryngol. 2014;271(2):385–90. doi: 10.1007/s00405-013-2542-9.
Adams MT, Saltzman B, Perkins JA. Head and Neck Lymphatic Malformation Treatment. Otolaryngol Head Neck Surg. 2012;147(4):627–39.
Love Z. Hsu D. Low-flow vascular malformations of the head and neck: clinicopathology and image guided therapy. J Neurointerv Surg. 2012;4(6):414-25. doi: 10.1136/neurintsurg-2011-010126.
Malic CC, Guilfoyle R, Courtemanche RJM, Arneja JS, Heran MKS, Courtemanche DJ. Lymphatic Malformation Architecture. J Craniofac Surg. 2017;28(7):1721–1724. doi: 10.1097/SCS.0000000000003789.
Acevedo JL, Shah RK, Brietzke SE. Nonsurgical therapies for lymphangiomas: A systematic review. Otolaryngol Head Neck Surg. 2008;138(4):418–24. doi: 10.1016/j.otohns.2007.11.018.
Horbach SE, Lokhorst MM, Saeed P, de Goüyon Matignon de Pontouraude CM, Rothová A, van der Horst CM. A. Sclerotherapy for low-flow vascular malformations of the head and neck: A systematic review of sclerosing agents. J Plast Reconstr Aesthet Surg. 2016;69(3):295–304. doi: 10.1016/j.bjps.2015.10.045.
Wiegand S, Eivazi B, Sel S, Renz H, Werner JA, Folz BJ. Analysis of Cytokine Levels in Human Lymphangiomas. In Vivo. 2008;22(2):253–6.
Ogita S, Tsuto T, Deguchi E, Tokiwa K, Nagashima M, Iwai N. OK 432 therapy for unresectable lymphangiomas in children. J Pediatr Surg. 1991;26(3):263–8.
Ghaffarpour N, Petrini B, Svensson LA, Boman K, Wester T, Claesson G. Patients with lymphatic malformations who receive the immunostimulant OK-432 experience excellent long-term outcomes. Acta Paediatr. 2015;104(11):1169–73. doi: 10.1111/apa.13086.
Ogita S, Tsuto T, Tokiwa K, Takahashi T. Intracystic injection of OK-432: a new sclerosing therapy for cystic hygroma in children. Br J Surg. 1987;74(8):690–1.
Benzar I. Treatment of Lymphatic malformations with OK-432: the First Experience of a Single Hospital. Internat J of Biomed. 2014;4(4):237–41.
Ogita S, Tsuto T, Nakamura K, Deguchi E, Iwai N. OK-432 therapy in 64 patients with lymphangioma. J Pediatr Surg. 1994;29(6):784–5.
Poldervaart MT, Breugem CC, Speleman L, Pasmans S. Treatment of Lymphatic Malformations With OK-432 (Picibanil). J Craniofac Surg. 2009;20(4):1159–62. doi: 10.1097/SCS.0b013e3181abb249.
Tu JH, Do HM, Patel V, Yeom KW, Teng JMC. Sclerotherapy for lymphatic malformations of the head and neck in the pediatric population. J Neurointerv Surg. 2017;9(10):1023–1026. doi: 10.1136/neurintsurg-2016-012660.
Smith MC, Zimmerman MB, Burke DK, Bauman NM, Sato Y, Smith RJ. Efficacy and safety of OK-432 immunotherapy of lymphatic malformations. Laryngoscope. 2009;119(1):107–15. doi: 10.1002/lary.20041.
Kim DW. OK-432 sclerotherapy of lymphatic malformation in the head and neck: factors related to outcome. Pediatr Radiol. 2014;44(7):857–62. doi: 10.1007/s00247-014-2889-0.
Trenor CC 3rd, Chaudry G. Complex lymphatic anomalies. Semin Pediatr Surg. 2014;23(4):186–90. doi: 10.1053/j.sempedsurg.2014.07.006.
Downloads
Published
How to Cite
Issue
Section
License
Authors who sent their manuscript to International Journal of Medicine and Medical Research agree to the following terms:
1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC-BY-NC that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
2. Authors able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
